Should We Extend the Use of Oral Antibiotics in Infective Endocarditis? The ENDO-ORAL Study
Clinical Infectious Diseases · 17.03.2026 · 82 (3) · e462-e470
DOI: 10.1093/cid/ciaf452 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 18.08.2025. Verfasst von Benoit Rallet und 8 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Disease Department, Dijon Bourgogne University Hospital, Dijon Cedex, France. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Endocarditis, Endocarditis, Bacterial. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Switching to oral therapy has become an option for treating infective endocarditis (IE) in well-selected patients. This study aimed to assess its effectiveness in real-life settings, including patients who would not have been eligible under current guidelines based on the POET trial results.
Methods
All adults treated for IE in two French tertiary centers from January 2016 to December 2023 were included in a retrospective cohort. For each participant, clinical, microbiological, and therapeutic data were collected retrospectively. Patients who received at least 10 days of effective antibiotic therapy were included and categorized based on the route of administration (exclusively intravenous or with a switch to oral therapy). POET-ineligible patients were those who were not eligible in the POET trial. Treatment failure (death, recurrence, or need for suppressive therapy, within 3 months following completion of the initial antibiotic course) was assessed using propensity score (PS) analysis, with oral switch as a time-dependent variable.
Results
Three hundred and thirty-three participants were included (233 in the intravenous group and 100 patients in the oral group). No significant difference in treatment failure was observed between groups after adjustment using a PS (HR = 0.55 in favor of oral switch, 95% CI = .27–1.17). The results were similar in the POET-ineligible subgroup, which accounted for 44.7% of participants. Days alive outside the hospital were significantly higher in the oral group (59 vs 47 days, P = .001).
Conclusions
Oral switch is a suitable option beyond “classical” frontiers in the management of IE, with potential direct and indirect benefits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infectious Disease Department, Dijon Bourgogne University Hospital, Dijon Cedex, France.
- Department of Internal Medicine, Infectious Diseases and Clinical Immunology, CHU Reims Reims, France.
- Methodological Support Unit, University of Reims Champagne-Ardenne, VieFra, CHU Reims Reims, France.
- INSERM CIC 1432, Université de Bourgogne Europe, Dijon, France.
- Department of Internal Medicine, Infectious Diseases and Clinical Immunology, University of Reims Champagne-Ardenne, VieFra, CHU Reims, Reims, France.
ORCID-Profile: Benoit Rallet, Firouzé Bani-Sadr, Thibault Sixt, Marin Moutel, Lionel Piroth, Maxime Hentzien
Zitieren
APA
Rallet, B., Pouy, R., Coutureau, C., Blot, M., Bani-Sadr, F., Sixt, T., Moutel, M., Piroth, L., & Hentzien, M. (2026). Should We Extend the Use of Oral Antibiotics in Infective Endocarditis? The ENDO-ORAL Study. Clinical Infectious Diseases, 82(3), e462-e470. https://doi.org/10.1093/cid/ciaf452
Vancouver
Rallet B, Pouy R, Coutureau C, Blot M, Bani-Sadr F, Sixt T, et al. Should We Extend the Use of Oral Antibiotics in Infective Endocarditis? The ENDO-ORAL Study. Clinical Infectious Diseases. 2026;82(3):e462-e470. doi:10.1093/cid/ciaf452
BibTeX
@article{Rallet2026,
author = {Rallet, Benoit and Pouy, Romane and Coutureau, Claire and Blot, Mathieu and Bani-Sadr, Firouzé and Sixt, Thibault and Moutel, Marin and Piroth, Lionel and Hentzien, Maxime},
title = {Should We Extend the Use of Oral Antibiotics in Infective Endocarditis? The ENDO-ORAL Study},
journal = {Clinical Infectious Diseases},
year = {2026},
volume = {82},
number = {3},
pages = {e462--e470},
doi = {10.1093/cid/ciaf452}
}
EUVIMED